

UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	
09/555,349	08/01/00	TEDDER		T	180/95/PCT/U
			_ ¬ [EXAMINER	
HM22/0320 ARLES A TAYLOR JR			u I	ART UNIT	PAPER NUMBER
JENKINS & WILSON UNIVERSITY TOWER 3100 TOWER BOULEVARD SUITE 1400			1632	8	
DURHAM NC 2	7707			DAIL MAILLE	03/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant(s)
		09/555,349	TEDDER, THOMAS F.
	Office Action Summary	Examiner	Art Unit
		Q. Janice Li	1632
	The MAILING DATE of this communication app	pears on the cover she	et with the correspondence address
Period fo	r Reply		
THE N - Exten after S - If tho - If NO - Failur - Any f	DRTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. isions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reperiod for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statuely received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	. 136 (a). In no event, however, ply within the statutory minimurd will apply and will expire SIX (may a reply be timely filed n of thirty (30) days will be considered timely. 6) MONTHS from the mailing date of this communication. come ABANDONED (35 U.S.C. § 133).
1)	Responsive to communication(s) filed on	·	
2a) <u></u>	THIS dollars to the second	This action is non-final	
3)	Since this application is in condition for allow closed in accordance with the practice under	wance except for form er <i>Ex parte Quayle</i> , 19	al matters, prosecution as to the merits is 35 C.D. 11, 453 O.G. 213.
Dispositi	on of Claims		
4) 🛛	Claim(s) 1-28 is/are pending in the application	on.	
	4a) Of the above claim(s) is/are withdr	rawn from consideration	on.
5)	Claim(s) is/are allowed.		
6)	Claim(s) is/are rejected.		
	Claim(s) is/are objected to.		
8)🛛	Claims <u>1-28</u> are subject to restriction and/o	r election requirement	i.
Applicat	ion Papers		
9)[The specification is objected to by the Exam	iner.	
10)	The drawing(s) filed on is/are objecte	d to by the Examiner.	_
11)	The proposed drawing correction filed on	is: a)□ approve	d b) disapproved.
12)	The oath or declaration is objected to by the	Examiner.	
Priority	under 35 U.S.C. § 119		
	Acknowledgment is made of a claim for fore	ign priority under 35 U	J.S.C. § 119(a)-(d) or (f).
	o☐ All b)☐ Some * c)☐ None of:		
,	1. Certified copies of the priority docume	ents have been receiv	ed.
	2. Certified copies of the priority docume	ents have been receiv	ed in Application No
د إ	Copies of the certified copies of the p application from the International See the attached detailed Office action for a l	riority documents have Bureau (PCT Rule 17	e been received in this National Stage .2(a)).
14)[_ <u>]</u>	Acknowledgement is made of a daim for do	micono priority ariability	• .,
Attachme	nt(s)		
15) 🗍 No	otice of References Cited (PTO-892)	· ==	Interview Summary (PTO-413) Paper No(s)
16) No	otice of Draftsperson's Patent Drawing Review (PTO-948 formation Disclosure Statement(s) (PTO-1449) Paper No	' -	Notice of Informal Patent Application (PTO-152) Other:

Application/Control Number: 09/555,349

Art Unit: 1632

DETAILED ACTION

Election/Restrictions

- 1. This application contains the following inventions or groups of inventions, which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, restriction is required.
 - Claims 1-13 are drawn to a method for production of monoclonal antibody using a CD19 transgenic mouse. Classified in class 800, subclass 6.
 - II. Claims 14-18 are drawn to a method of making <u>polyclonal antibody</u> in an animal (wild-type or transgenic). Classified in class 800, subclass 4.
 - III. Claims 19-25 are drawn to <u>a diagnostic assay kit</u> comprising the antibodies, monoclonal and/or polyclonal. Classified in class 435, subclass 975.
 - IV. Claims 26-28 are drawn to a method for producing non-human <u>transgenic</u> <u>animals</u>. Classified in class 800, subclass 22.
 - V. Claims 26-27 are drawn to a method for producing <u>non-human animals excluding</u> <u>transgenic animals</u>. Classified in class 800, subclass 8.
- 2. The invention listed as groups do not relate to a single inventive concept under PCT Rule 13.1, because under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I does not share a special technical feature with group II because the two methods produce different products (monoclonal vs. polyclonal antibodies) and have different method steps. 37 CFR 1.475 does not recognize the unity of invention between

Application/Control Number: 09/555,349

Art Unit: 1632

two different methods even though they may use the same starting material, in the instant case, CD19 transgenic animal. Group III are a diagnostic assay kit, which could use the products of either or both Groups I and II. Groups IV and V do not share the common inventive concept because the method of making a transgenic animal is distinct from the method of breading a wild-type animal, different method steps are used and different issues have to be addressed and different products are made.

Applicants are referred to 37 CFR 1.475 (a)-(d) for details. 37 CFR 1.475 (a) recites "An international and a national stage application shall related to <u>one invention</u> only or to a group of inventions so linked as to form a single general inventive concept ('requirement of unity of invention'). ..." 37 CFR 1.475 (b) does not provide for more than one product as a combination of invention. Groups I-V do not share the common inventive concept or special technical feature with, unity of invention is lacking.

3. A telephone call was made to Arles Taylor on March 12, 2001 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is advised that where a single claim encompasses more than one invention as defined above, upon election of an invention for examination, said claim will only be examined to the extent that it reads upon the elected invention.

Art Unit: 1632

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Q. Janice Li whose telephone number is 703-308-7942. The examiner can normally be reached on 8:30 am - 5 pm, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Karen M Hauda can be reached on 703-305-6608. The fax numbers for the organization where this application or proceeding is assigned are 703-308-8724 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of formal matters can be directed to the patent analyst, Kay Pinsky, whose telephone number is (703) 305-3553.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196. The faxing of such papers must conform to the notice published in the Official Gazette 1096 OG 30 (November 15, 1989).

Q. Janice Li Examiner Art Unit 1632

SCOTT D. PRIEBE, PH.D PRIMARY EXAMINER

Sertt D. Pribe